Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Exelixis, Inc.

EXELNASDAQ
Healthcare
Biotechnology
$44.21
$0.05(0.11%)
U.S. Market is Open • 12:31

Exelixis, Inc. Fundamental Analysis

Exelixis, Inc. (EXEL) shows strong financial fundamentals with a PE ratio of 15.13, profit margin of 33.73%, and ROE of 36.89%. The company generates $2.3B in annual revenue with strong year-over-year growth of 18.49%.

Key Strengths

ROE36.89%
Operating Margin37.59%
PEG Ratio0.86
Current Ratio3.56

Areas of Concern

No major concerns flagged.
We analyze EXEL's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 87.4/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B+
87.4/100

We analyze EXEL's fundamental strength across five key dimensions:

Efficiency Score

Excellent

EXEL demonstrates superior asset utilization.

ROA > 10%
27.51%

Valuation Score

Excellent

EXEL trades at attractive valuation levels.

PE < 25
15.13
PEG Ratio < 2
0.86

Growth Score

Moderate

EXEL shows steady but slowing expansion.

Revenue Growth > 5%
18.49%
EPS Growth > 10%
1.77%

Financial Health Score

Excellent

EXEL maintains a strong and stable balance sheet.

Debt/Equity < 1
0.08
Current Ratio > 1
3.56

Profitability Score

Excellent

EXEL achieves industry-leading margins.

ROE > 15%
36.89%
Net Margin ≥ 15%
33.73%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is EXEL Expensive or Cheap?

P/E Ratio

EXEL trades at 15.13 times earnings. This indicates a fair valuation.

15.13

PEG Ratio

When adjusting for growth, EXEL's PEG of 0.86 indicates potential undervaluation.

0.86

Price to Book

The market values Exelixis, Inc. at 5.48 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

5.48

EV/EBITDA

Enterprise value stands at 12.84 times EBITDA. This signals the market has high growth expectations.

12.84

How Well Does EXEL Make Money?

Net Profit Margin

For every $100 in sales, Exelixis, Inc. keeps $33.73 as profit after all expenses.

33.73%

Operating Margin

Core operations generate 37.59 in profit for every $100 in revenue, before interest and taxes.

37.59%

ROE

Management delivers $36.89 in profit for every $100 of shareholder equity.

36.89%

ROA

Exelixis, Inc. generates $27.51 in profit for every $100 in assets, demonstrating efficient asset deployment.

27.51%

Following the Money - Real Cash Generation

Operating Cash Flow

Exelixis, Inc. generates strong operating cash flow of $873.02M, reflecting robust business health.

$873.02M

Free Cash Flow

Exelixis, Inc. generates strong free cash flow of $848.25M, providing ample flexibility for dividends, buybacks, or growth.

$848.25M

FCF Per Share

Each share generates $3.16 in free cash annually.

$3.16

FCF Yield

EXEL converts 7.33% of its market value into free cash.

7.33%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

15.13

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.86

vs 25 benchmark

P/B Ratio

Price to book value ratio

5.48

vs 25 benchmark

P/S Ratio

Price to sales ratio

5.04

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.08

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.56

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.37

vs 25 benchmark

ROA

Return on assets percentage

0.28

vs 25 benchmark

ROCE

Return on capital employed

0.36

vs 25 benchmark

How EXEL Stacks Against Its Sector Peers

MetricEXEL ValueSector AveragePerformance
P/E Ratio15.1329.43 Better (Cheaper)
ROE36.89%800.00% Weak
Net Margin33.73%-20145.00% (disorted) Strong
Debt/Equity0.080.30 Strong (Low Leverage)
Current Ratio3.564.64 Strong Liquidity
ROA27.51%-17936.00% (disorted) Strong

EXEL outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Exelixis, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

133.79%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

69.41%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

38.58%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ